NHS could recoup cost of ineffective drugs
The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- 10 expert briefings every fortnight (Premium only)
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)
Already a subscriber? Sign into your account here